HDL-P Test

Your standard lipid panel reports HDL cholesterol (HDL-C), the amount of cholesterol riding inside your protective HDL particles. But two people with identical HDL-C numbers can have very different numbers of actual HDL particles, and it is the particle count that more closely tracks real-world protection against heart disease, heart failure, and even death. When HDL-C looks normal but your particle count is low, you may be carrying less cardiovascular protection than your numbers suggest.

HDL-P (high-density lipoprotein particle number) counts how many of these particles are circulating in your blood, typically measured by a technology called NMR (nuclear magnetic resonance) spectroscopy. Because HDL particles do far more than just carry cholesterol, this count captures protective biology that a simple cholesterol measurement misses.

What HDL Particles Actually Do

HDL particles are not a single molecule. They are tiny complexes of protein and fat, roughly half of each, built around a core protein called apolipoprotein A-I (apoA-I). Your liver and intestines produce the initial particles, and enzymes in your blood then reshape them into a range of sizes, from extra-small to very large.

Their most recognized job is reverse cholesterol transport: pulling excess cholesterol out of artery walls and ferrying it back to the liver for disposal. But HDL particles also dampen inflammation, protect the lining of blood vessels from damage, resist blood clot formation, and even help your immune system fight infections. Which of these jobs a particle performs depends partly on its size and the proteins it carries, not on how much cholesterol is packed inside.

This is the central insight behind HDL-P testing. Two people with the same HDL-C could have very different numbers of particles doing this work. The person with more particles, especially small ones, generally has a more active cholesterol-removal and anti-inflammatory system.

Heart Disease and Coronary Events

In the MESA study (Multi-Ethnic Study of Atherosclerosis), which followed about 5,600 adults from diverse ethnic backgrounds, higher HDL-P was independently linked to less plaque buildup in the carotid arteries, the major vessels feeding the brain. After adjusting for other lipid markers, HDL-P remained a stronger predictor of coronary events than HDL-C alone. Smaller HDL particles showed a particularly strong inverse relationship with artery wall thickening.

Among people already taking a potent statin, HDL-P remained a reliable signal of who still had residual cardiovascular risk. In an analysis from the JUPITER trial, which randomized nearly 18,000 adults to rosuvastatin or placebo, on-treatment HDL-P predicted future cardiovascular events while HDL-C and apoA-I did not, once other lipids were accounted for. If you are on a statin and want to know whether your residual risk is truly low, HDL-P gives you information your standard panel cannot.

A 2018 meta-analysis pooling data from multiple cardiovascular cohorts confirmed the pattern: higher total HDL-P was inversely related to cardiovascular events. The protective signal was strongest for small and total HDL particles.

The Size Paradox: Small Particles Protect, Large Ones May Not

This is one of the most counterintuitive findings in lipid science. In many conditions, it is the smaller HDL particles that are most protective, while very large HDL particles are neutral or even associated with worse outcomes. A 2025 meta-analysis of patients with existing cardiovascular disease found that higher small and total HDL-P were linked to lower all-cause and cardiovascular death, while large HDL-P was associated with higher all-cause mortality.

Why would bigger particles be worse? The answer is not that large HDL directly causes harm. Instead, an abundance of large particles often reflects a metabolic state where HDL particles are not cycling efficiently. Small HDL particles are the ones that actively pull cholesterol from artery walls through a transporter protein on cells called ABCA1, which acts as a doorway for cholesterol to leave cells and attach to HDL. Once loaded, the particles grow larger. If large particles accumulate rather than being cleared and recycled, it can signal that the system is sluggish, not that it is working well.

This means HDL-P is not a simple "higher is always better" marker. What matters most is having plenty of small and medium particles actively doing the work of cholesterol removal and vessel protection. A high total HDL-P driven by small particles is a different, more favorable signal than a high HDL-P driven by large particles.

Type 1 and Type 2 Diabetes

Diabetes reshapes HDL particles in ways that HDL-C alone cannot detect. In a cohort of 550 adults with type 1 diabetes, extra-small HDL-P was the strongest inverse predictor of coronary artery disease, far outperforming HDL-C or apoA-I. The protective effect was traced to these small particles' ability to accept cholesterol through the ABCA1 transporter, the first step in reverse cholesterol transport.

In type 2 diabetes, the story is similar. An analysis of nearly 2,000 adults from the Hong Kong Diabetes Biobank found that small HDL particles were inversely associated with cardiovascular events and all-cause death, and improved risk classification beyond standard models. Very large HDL particles, by contrast, were linked to higher mortality. If you have diabetes, your HDL-C number may look acceptable while your actual particle protection is compromised.

Heart Failure

A multicohort analysis of nearly 17,000 adults across four studies found that higher HDL-P predicted lower risk of developing heart failure. Larger HDL particle size and a higher ratio of HDL cholesterol to HDL particle number (meaning fewer, fatter particles) were associated with increased heart failure risk. HDL-C itself showed no independent association with heart failure at all. This is a case where HDL-P reveals a risk that HDL-C completely misses.

Kidney Disease

In the PREVEND study, which followed over 4,100 adults without kidney disease, higher total HDL-P and certain medium-sized subspecies were modestly protective against developing chronic kidney disease (CKD). One larger HDL subspecies, however, was linked to increased CKD risk. The pattern mirrors what is seen in cardiovascular disease: more total particles and more small-to-medium particles tend to be protective, while an excess of the largest particles may not be.

Infections and Immune Defense

HDL particles carry proteins and lipids that help your immune system respond to threats. A study of over 30,000 adults found that people with lower numbers of small and medium HDL particles had higher rates of pneumonia, sepsis, and infection-related hospitalization. Large and extra-large HDL particles did not show this protective pattern. A separate genetic analysis suggested that some of this link may reflect underlying inflammation (specifically signaling through a molecule called IL-6, a chemical messenger that drives the body's inflammatory response) rather than a purely direct effect of HDL particles on infection risk.

Menopause and HDL Changes

The SWAN-HDL study followed 471 women through the menopause transition and found that while HDL-C increased during menopause, the underlying HDL particle composition shifted in unfavorable directions. HDL subclasses and lipid content changed in ways that could reduce protective function, even as the headline HDL-C number looked better. For women going through or past menopause, a rising HDL-C may mask deteriorating HDL quality that only particle-level testing can reveal.

Reference Ranges

There are no universally accepted clinical cutpoints for HDL-P comparable to those for LDL cholesterol or HbA1c. Major cardiovascular guidelines base treatment thresholds on LDL-C, non-HDL-C, and ApoB, not HDL-P. The values below come from research cohorts measured by NMR spectroscopy and are meant as orientation, not fixed targets. Your lab may report different units or ranges depending on the platform used.

Because absolute values differ between NMR platforms and even between software versions from the same manufacturer, the most meaningful comparison is your own result tracked over time within the same lab. Different measurement technologies (NMR, ion mobility, and gel electrophoresis, each of which counts and sizes particles differently) can give substantially different numbers for the same blood sample, so switching labs or platforms mid-stream makes trending unreliable.

When Results Can Be Misleading

Several factors can shift your HDL-P reading without reflecting a true change in your cardiovascular protection:

• Measurement platform differences: NMR-based HDL-P shows substantial discrepancies compared with other laboratory techniques (such as ion mobility) in estimating both particle number and size. A result from one platform is not directly comparable to a result from another.
• Acute inflammation or illness: Conditions like active infection, recent surgery, or flares of chronic disease can temporarily suppress HDL-P by altering liver production and increasing HDL clearance. Test when you are in your usual state of health.
• Alcohol intake: Alcohol consumption influences HDL-P levels and was identified as a confounder in the PREVEND study. Consistent habits before each draw improve comparability.
• Medications: Several drugs shift HDL-P without that being their intended purpose. PCSK9 inhibitors (like alirocumab) can increase total HDL-P by about 11%. Obeticholic acid, used for liver disease, reduces total HDL-P, especially large and medium particles, though levels normalize after stopping the drug. SGLT2 inhibitors (such as dapagliflozin) shift HDL cholesterol subfraction distribution (raising HDL2 cholesterol content without changing HDL3 cholesterol), though this was measured by cholesterol subfractions rather than NMR particle counts. If you start or stop any of these, retest after levels have stabilized.

Tracking Your Trend

A single HDL-P reading is a snapshot, not a verdict. Because NMR platforms can vary and because HDL-P responds to diet, exercise, weight changes, and medications, tracking your number over time within the same lab gives you far more useful information than any isolated result.

Get a baseline when you are healthy and in your usual routine. If you are making lifestyle changes or starting a new medication, retest in 3 to 6 months to see whether the needle moved. After that, annual testing is reasonable for most people. If you have diabetes, established heart disease, or heart failure, more frequent monitoring (every 6 months) can help you and your clinician see whether your HDL particle profile is improving or deteriorating alongside your other risk markers.

The trending approach is especially valuable for HDL-P because standardized clinical cutpoints do not yet exist. Your trajectory, whether your small HDL-P is rising, stable, or falling, tells you more than where a single reading falls on a population-based reference range.

What to Do With Your Results

If your HDL-P is low, especially if your small HDL-P is low while your HDL-C looks normal, that discordance is a signal worth investigating. The next step is to ensure your atherogenic particle burden is also assessed: ApoB or LDL-P will tell you about the harmful side of the equation, while hs-CRP (high-sensitivity C-reactive protein) captures inflammatory risk that can worsen HDL function.

A lipidologist, a physician who specializes in cholesterol and lipoprotein disorders, is the right specialist if your HDL particle profile is persistently abnormal or discordant with your standard lipids. They can interpret the NMR subclass data in context and determine whether your pattern reflects metabolic syndrome, diabetes-related HDL dysfunction, or another treatable condition.

If your HDL-P is in a favorable range, with plenty of small and total particles, that is genuinely reassuring, especially if your ApoB and inflammatory markers are also well controlled. Continue tracking annually to confirm the trend holds.